<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755480</url>
  </required_header>
  <id_info>
    <org_study_id>14-7420</org_study_id>
    <nct_id>NCT02755480</nct_id>
  </id_info>
  <brief_title>Ultralow Dose Thoracic Computed Tomography in Immunocompromised Patients</brief_title>
  <acronym>ULDCT-IC</acronym>
  <official_title>Ultralow Dose Thoracic Computed Tomography in Immunocompromised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with bone marrow cancer are more susceptible to chest infections than healthy
      adults; marrow ablation treatment further compromises their immune status and increases the
      risk of fungal opportunistic infection, which is associated with a high fatality rate.
      Therefore, it is critical to achieve early and accurate diagnosis of fungal infection when
      these patients become febrile. At the Mount Sinai Hospital (MSH) and the University Health
      Network (UHN), the standard of care (SOC) to exclude a chest infection in immunocompromised
      (IC) patients is chest computed tomography (CT) using low dose CT (LDCTT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As patients may have several febrile episodes during their hospital stay, the cumulative dose
      from LDCTT scans can be significant and increase the lifetime risk of inducing a second
      cancer. The aim of this project is to determine whether a 75% reduction in radiation dose for
      LDCTT in other words, an ultralow dose chest CT (uLDCTT) at a dose comparable to chest X-ray,
      maintains the diagnostic image quality for detection of fungal chest infection in IC
      patients. If successful, uLDCTT will be adopted as SOC imaging at Princess Margaret Cancer
      Center (PM) for these patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI has left UHN. This study is no longer running at UHN.
  </why_stopped>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image acquisition</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Perform paired clinical low dose (LDCTT) and research ultralow dose (uLDCTT) chest CT in immunocompromised (IC) patients who present with febrile neutropenia (FN) and are clinically referred for LDCTT to exclude opportunistic fungal infection.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>ultralow dose research</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An Ultralow Dose Thoracic Computed Tomography scan will be added to the standard of care Low dose CT scan.
The image quality of the ultralow dose CT will be compared to the Low dose thoracic Computed Tomography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultralow Dose Thoracic Computed Tomography</intervention_name>
    <description>Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays</description>
    <arm_group_label>ultralow dose research</arm_group_label>
    <other_name>Ultralow dose CT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All immunocompromised patients clinically referred for LDCTT to the Medical Imaging
             department at PM

          2. 18 years and older

        Exclusion Criteria:

          1. Patients that cannot follow study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narinder Paul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital, Department of Medical Imaging</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>October 26, 2018</last_update_submitted>
  <last_update_submitted_qc>October 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone marrow transplant</keyword>
  <keyword>infection</keyword>
  <keyword>computed tomography</keyword>
  <keyword>radiation dose</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

